Rufinamide from clinical trials to clinical practice in the United States and Europe

Epileptic Disorders

Volumn 13, Issue , 2011, Pages S27-S43

  Resnick, Trevor ^a   Arzimanoglou, Alexis ^b   Brown, Lawrence W ^c   Flamini, Robert ^d   Kerr, Michael ^e   Kluger, Gerhard ^f   Kothare, Sanjeev ^g   Philip, Sunny ^h   Harrison, Miranda ⁱ   Narurkar, Milind ^j  

^a MIAMI CHILDREN'S HOSPITAL   (United States)

^b HOSPICES CIVILS DE LYON   (France)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^d CHILDREN'S HEALTHCARE OF ATLANTA   (United States)

^e CARDIFF UNIVERSITY   (United Kingdom)

^f Schön Klinik Vogtareuth   (Germany)

^g BOSTON CHILDREN S HOSPITAL   (United States)

^h Department of Dermatology   (United Kingdom)

ⁱ EISAI CO LTD   (Japan)

^j EISAI INC   (United States)

more..

Author keywords

Clinical practice; Clinical trials; Lennox Gastaut syndrome; Real world; Rufinamide

Indexed keywords

ANTICONVULSIVE AGENT; BENZODIAZEPINE DERIVATIVE; BROMIDE; CARBAMAZEPINE; CLOBAZAM; CLONAZEPAM; ETIRACETAM; FELBAMATE; LAMOTRIGINE; OXCARBAZEPINE; PLACEBO; RUFINAMIDE; TOPIRAMATE; VALPROIC ACID; ZONISAMIDE; TRIAZOLE DERIVATIVE;

ADD ON THERAPY; ANOREXIA; BLURRED VISION; CEREBELLUM DISEASE; CLINICAL TRIAL (TOPIC); DIZZINESS; DRESS SYNDROME; DROP ATTACK; DRUG CHOICE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; EUROPE; FATIGUE; FEVER; HEADACHE; HUMAN; INFECTION; LENNOX GASTAUT SYNDROME; LETHARGY; NAUSEA; PRIORITY JOURNAL; PROBLEM BEHAVIOR; RASH; RECOMMENDED DRUG DOSE; REVIEW; SEDATION; SEIZURE; SIDE EFFECT; SLEEP DISORDER; SOMNOLENCE; UNITED STATES; UNSTEADY GAIT; VOMITING; CHILD; INFANTILE SPASM; MENTAL DEFICIENCY; PATHOPHYSIOLOGY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ANTICONVULSANTS; CHILD; CHILD, PRESCHOOL; EUROPE; HUMANS; MENTAL RETARDATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SEIZURES; SPASMS, INFANTILE; TREATMENT OUTCOME; TRIAZOLES; UNITED STATES;

EID: 80052566407     PISSN: 12949361     EISSN: 19506945     Source Type: Journal    
DOI: 10.1684/epd.2011.0421     Document Type: Review

References (31)

1. Arzimanoglou A, French J, Blume WT, et al. Lennox-Gastaut syndrome: a consensus approach on diagnosis, assessment, management, and trial methodology. Lancet Neurol 2009;8:82-93.
2. Awadh M, Jain V, Vora N, et al. Scottish experience with rufinamide in children with refractory drop attacks. Poster presented at the 8th Congress of the European Paediatric Neurology Society, 30 September - 3 October 2009, Harrogate, United Kingdom.
3. ™ Prescribing Information. Eisai Inc, October 2010. Available at: http://www.banzel.com/Docs/Pdf/BanzelPI.pdf. Accessed 06 January 2011.
4. Bruno PL, Venna P, Hirshberg J, Paolini J, Thibert R, Thiele E. Clinical experience with rufinamide (Banzel) in patients with intractable epilepsy. Epilepsia 2009;50(Suppl. 11):424 (abstract 3.225).
5. Cantarín V, García-Peñas J, Ruiz-Falcó M, et al. Rufinamide in children with Lennox-Gastaut syndrome and other related refractoryepileptic encephalopathies: a prospective, add-on, open-label treatment study. Epilepsia 2009;50(Suppl. 10):149 (abstract p682).
6. Coppola G, Grosso S, Franzoni E, et al. Rufinamide in children and adults with Lennox-Gastaut syndrome: First Italian multicenter experience. Seizure 2010;19:587-91.
7. Ferrie CD, Patel A. Treatment of Lennox-Gastaut Syndrome (LGS). Eur J Paediatr Neurol 2009;13:493-504.
8. French JA, Kanner AM, Bautista J, et al. Efficacy and tolerability of the new antiepileptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62:1261-73.
9. Friedo A, Bohlmann K, Straub H. First experiences with rufinamide - tolerability and effectiveness in clinical practice. Epilepsia 2009;50(Suppl. 4):195 (abstract E539).
10. Ghacibeh GA, Fertig E, Kulikova R. Exacerbation of seizures after additionofrufinamide. Epilepsia 2009;50(Suppl. 11):256 (abstract 2.220).
11. Glauser T, Kluger G, Sachdeo R, Krauss G, Perdomo C, Arroyo S. Rufinamide for generalized seizures associated with Lennox-Gastaut syndrome. Neurology 2008;70:1950-8.
12. Hakimian S, Cheng-Hakimian A, Anderson GD, Miller JW. Rufinamide: a new anti-epileptic medication. Expert Opin Pharmacother. 2007;8:1931-40.
13. Hancock EC, Cross HH. Treatment of Lennox-Gastaut syndrome. Cochrane Database Syst Rev 2009; (3): CD003277.
14. ® Summary of Product Characteristics. Eisai Ltd, 2007. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Product-Information/human/000660/WC500032937.pdf. Accessed 06 January 2011.
15. Jain KK. An assessment of rufinamide as an anti-epileptic in comparison with other drugs in clinical development. Expert Opin Investig Drugs 2000;9:829-40.
16. Kluger G, Kurlemann G, Haberlandt E, et al. Effectiveness and tolerability of rufinamide in children and adults with refractory epilepsy: first European experience. Epilepsy Behav 2009;14:491-5.
17. Kluger G, Glauser T, Krauss G, Seeruthun R, Perdomo C, Arroyo S. Adjunctive rufinamide in Lennox-Gastaut syndrome: a long-term, open-label extension study. Acta Neurol Scand 2010a; 122:202-8.
18. Kluger G, Haberlandt E, Kurlemann G, et al. First European long-term experience with the orphan drug rufinamide in childhood-onset refractory epilepsy. Epilepsy Behav 2010b; 17:546-8.
19. Lund C, Lossius M. Efficacy and tolerability of rufinamide in adults with Lennox-Gastaut syndrome or Lennox-Gastautlike conditions. Epilepsia 2009;50(Suppl. 10):39 (abstract p161).
20. Mahendrakar R, Scott RC, Aylett SE, Das KB. Rufinamide as add on therapy in children and adolescents with drug resistant epilepsy and learning difficulties. Epilepsia 2010;51(Suppl. 4):117 (abstract p397).
21. Marchand M, Fuseau E, Critchley DJ. Supporting the recommended paediatric dosing regimen for rufinamide in Lennox-Gastaut syndrome using clinical trial simulation. J Pharmacokinet Pharmacodyn 2010;37:99-118.
22. Miller-Horn J, Spiegel R, Bello L, Andriola M. Clinical experience with rufinamide in an academic medical center. Epilepsia 2009;50(Suppl. 11):253 (abstract 2.211).
23. Nakken O, Eriksson A, Lossius M, Nakken K. Rufinamide as add-on treatment for patients with Lennox-Gastaut syndrome. Epilepsia 2009;50(Suppl. 10):153 (abstract p705).
24. Ryzí M, Ošlejšková H, Cahová P. Clinical experience with rufinamide (Inovelon) in therapy of Lennox-Gastaut syndrome. Epilepsia 2009;50(Suppl. 10):165 (abstract p762).
25. Seeruthun R, Yeates A, Ashworth S. A European registry of antiepileptic drug use in patients with Lennox-Gastaut syndrome. Epilepsia 2009;50(Suppl. 10):35 (abstract p140).
26. Straub H-B, Friedo A-L, Bohlmann K. Effectiveness of rufinamide in different epilepsy syndromes. Epilepsia 2010;51(Suppl. 4):74 (abstract p250).
27. van Rijckevorsel K. Treatment of Lennox-Gastaut syndrome: overview and recent findings. Neuropsychiatr Dis Treat 2008;4:1001-19.
28. Vendrame M, Loddenkemper T, Gooty VD, et al. Experience with rufinamide in a pediatric population: a single center's experience. Pediatr Neurol 2010;43:155-8.
29. Wheless JW, Clarke DF, Carpenter D. Treatment of pediatric epilepsy: expertopinion, 2005. J Child Neurol 2005;20(Suppl. 1):S1-S56.
30. Wheless JW, Clarke DF, Arzimanoglou A, Carpenter D. Treatment of pediatric epilepsy: European expert opinion, 2007. Epileptic Disord 2007;9:353-412.
31. Wiemer-Kruel A, Fahrbach J, Dönmez S, Mann F, Ernst J. First experiences with rufinamide in Lennox-Gastaut syndrome in children of the Epilepsy Center Kork. Epilepsia 2009;50(Suppl. 4):135 (abstract T319).